A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome

Sponsor
University College, London (Other)
Overall Status
Completed
CT.gov ID
NCT01647269
Collaborator
(none)
15
1
2
40
0.4

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate whether deep brain stimulation (DBS) of the globus pallidus internum (GPi) can alleviate tics in Gilles de la Tourette syndrome (GTS) and whether this treatment has any influence on social, psychological and behavioral disability and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Bilateral GPi Deep Brain Stimulation
Phase 2

Detailed Description

This study is aimed at adults who have severe Tourette syndrome and who have found that conventional treatments, such as drugs, do not control their symptoms sufficiently or cannot be tolerated.

The first two clinic visits will involve assessments. Participants will fill in a number of questionnaires and be examined by a psychiatrist and a neurologist. At the second visit, the patient will provide consent for participation and will undergo formal tests to find out if the participant is suitable and willing to undergo the research study and to record the type and severity of their Tourette syndrome symptoms.

The third visit will be an admission to hospital to have the deep brain stimulation (DBS) devices implanted. The admission to hospital should be around five days in duration.

At the first post operative follow-up visit, the patient will be placed into a "stimulator on" group or a "stimulator off" group. To try and make sure that these groups are the same to start with, each patient is put into a group by chance (randomly). This visit will take place around six weeks after surgery. In this trial, the participant will have an equal chance of being in the "on" or the "off" group first. This trial is also a "blinded" trial, neither the patient nor the researchers performing the assessments will know which group the patient is in.

At the next visit, 3 months later, the patient will have a further assessment. If their stimulators have been "on" for the first 3 months, they will be switched off. If they have been "off" they will be switched on.

At the next visit, 3 months later, the patient will be assessed again and then given the opportunity to carry on the trial with the stimulators switched on for long term follow up.

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomised, Controlled, Crossover Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Severe Tourette Syndrome
Study Start Date :
Jul 1, 2011
Actual Primary Completion Date :
Nov 1, 2014
Actual Study Completion Date :
Nov 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: DBS Off first

Procedure: Bilateral GPi Deep Brain Stimulation
Bilateral GPi Deep Brain Stimulation

Experimental: DBS On First

Procedure: Bilateral GPi Deep Brain Stimulation
Bilateral GPi Deep Brain Stimulation

Outcome Measures

Primary Outcome Measures

  1. Change in Yale Global Tic Severity Scale [Three months after stimulation switched ON v three months after stimulation switched OFF]

    The Change in Scores on the Yale Global Tic Severity Scale will be compared between defined periods with stimulation switched ON v stimulation switched OFF.

Secondary Outcome Measures

  1. Change in Modified Rush Video Rating scale [Three months after stimulation switched ON v three months after stimulation switched OFF]

  2. Change in Yale Brown Obsessive Compulsive Scale [Three months after stimulation switched ON v three months after stimulation switched OFF]

  3. Change in Neuropsychiatric Inventory [Three months after stimulation switched ON v three months after stimulation switched OFF]

  4. Change in Tourette Quality of life scale [Three months after stimulation switched ON v three months after stimulation switched OFF]

  5. Change in MOVES scale [Three months after stimulation switched ON v three months after stimulation switched OFF]

  6. Change in Beck Depression Inventory [Three months after stimulation switched ON v three months after stimulation switched OFF]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. The participant must be adult with stable Tourette syndrome.

  2. The participant must have a chronic and severe tic disorder with severe functional impairment, with a Yale Tourette Severity Scale score of at least 35/55 for at least 12 months prior to surgery.

  3. The participant must have failed conventional medical treatment at therapeutic doses of three classes of medication.

  4. The participant must not be suitable for behavioural intervention or that this intervention is inappropriate or unsuccessful.

  5. The participant must have been on stable and optimised treatment of co-morbid conditions for at least 6 months.

  6. The participant must be actively involved with and compliant with any psychosocial interventions.

  7. The patient must be compliant with treatment plans.

Exclusion Criteria:
  1. The tic disorder is attributable to any other condition.

  2. Any other medical or psychiatric disorders that substantially increase the risk of a failed procedure or that would significantly impede recovery.

  3. Psychosocial factors which might impede operative and post-operative care and research participation.

  4. Coagulation problems

  5. Other disease compromising life expectancy

  6. Patient likely to benefit from psychological intervention

  7. Patient unwilling to co-operate with post operative assessment and care

  8. Pregnancy.

  9. Participant under 20 years old.

Contacts and Locations

Locations

Site City State Country Postal Code
1 UCL Institute of Neurology London United Kingdom

Sponsors and Collaborators

  • University College, London

Investigators

  • Principal Investigator: Thomas Foltynie, MBBS PhD, UCL Institute of Neurology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University College, London
ClinicalTrials.gov Identifier:
NCT01647269
Other Study ID Numbers:
  • UCL 11/0226
First Posted:
Jul 23, 2012
Last Update Posted:
Mar 19, 2015
Last Verified:
Mar 1, 2015
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 19, 2015